CONTACT INFORMATION http://www.loyola.org
Joseph Clark
M.D.
  • Professor
  • Fellowship Program Director, Hematology/Oncology
  • Hematology/Oncology
Specialties
Kidney Cancer, Melanoma, Head and Neck Cancer
Board Certifications
  • Medical Oncology - Subspecialty Cert: AM Board of Internal Medicine
Research Keywords
  • Cancer/Carcinogenesis
  • Chemotherapeutic Agents
  • Cytokines
  • Immune System
  • Immunotherapy
  • Interferon
  • Melanoma
  • Vaccine
Publications

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialEscudier,B.; Michaelson,M. D.; Motzer,R. J.; Hutson,T. E.; Clark,J. I.; Lim,H. Y.; Porfiri,E.; Zalewski,P.; Kannourakis,G.; Staehler,M.; Tarazi,J.; Rosbrook,B.; Cisar,L.; Hariharan,S.; Kim,S.; Rini,B. I.British journal of cancer 2014 ; ( ):

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancerClark,J. I.; Greene,J. B.; Lau Clark,A.; Dalal,J. S.; Hofmeister,C. C.MEDICAL ONCOLOGY 2013 ;30(1):358-358

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialMargolin,K.; Ernstoff,M. S.; Hamid,O.; Lawrence,D.; McDermott,D.; Puzanov,I.; Wolchok,J. D.; Clark,J. I.; Sznol,M.; Logan,T. F.; Richards,J.; Michener,T.; Balogh,A.; Heller,K. N.; Hodi,F. S.The lancet oncology 2012 ;13(5):459-465

Evolving treatment strategies in thin cutaneous head and neck melanoma: 1 institution's experience.Jaber,J. J.; Clark,J. I.; Muzaffar,K.; Ruggiero,F. P.; Feustel,P. J.; Frett,M. J.; Zender,C. A.Head & neck 2011 ;33(1):7-12

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.Clark,J. I.; Moon,J.; Hutchins,L. F.; Sosman,J. A.; Kast,W. M.; Da Silva,D. M.; Liu,P. Y.; Thompson,J. A.; Flaherty,L. E.; Sondak,V. K.Cancer 2010 ;116(2):424-431

A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanomaLocke,F.; Clark,J. I.; Gajewski,T. F.CANCER CHEMOTHERAPY AND PHARMACOLOGY 2010 ;65(3):509-514

Improved survival with ipilimumab in patients with metastatic melanomaHodi,F. S.; O'Day,S. J.; McDermott,D. F.; Weber,R. W.; Sosman,J. A.; Haanen,J. B.; Gonzalez,R.; Robert,C.; Schadendorf,D.; Hassel,J. C.; Akerley,W.; van den Eertwegh,A. J.; Lutzky,J.; Lorigan,P.; Vaubel,J. M.; Linette,G. P.; Hogg,D.; Ottensmeier,C. H.; Lebbe,C.; Peschel,C.; Quirt,I.; Clark,J. I.; Wolchok,J. D.; Weber,J. S.; Tian,J.; Yellin,M. J.; Nichol,G. M.; Hoos,A.; Urba,W. J.The New England journal of medicine 2010 ;363(8):711-723

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryGunturu,K. S.; Meehan,K. R.; Mackenzie,T. A.; Crocenzi,T. S.; McDermott,D.; Usherwood,E. J.; Margolin,K. A.; Crosby,N. A.; Atkins,M. B.; Turk,M. J.; Ahonen,C.; Fuse,S.; Clark,J. I.; Fisher,J. L.; Noelle,R. J.; Ernstoff,M. S.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 ;28(7):1196-1202

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317Gordon,M. S.; Hussey,M.; Nagle,R. B.; Lara,P. N.,Jr; Mack,P. C.; Dutcher,J.; Samlowski,W.; Clark,J. I.; Quinn,D. I.; Pan,C. X.; Crawford,D.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 ;27(34):5788-5793

Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer.Clark,J. I.; Eisner,R. M.; Hofmeister,C.; Norton,J.; Thomas,S.; Choudhury,A.; Petruzzelli,G.; Lathers,D.; Young,M. R.; Lau,A.; Emami,B.American Journal of Clinical Oncology 2009 ;32(4):396-400

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyCohen,E. E.; Davis,D. W.; Karrison,T. G.; Seiwert,T. Y.; Wong,S. J.; Nattam,S.; Kozloff,M. F.; Clark,J. I.; Yan,D. H.; Liu,W.; Pierce,C.; Dancey,J. E.; Stenson,K.; Blair,E.; Dekker,A.; Vokes,E. E.The lancet oncology 2009 ;10(3):247-257

A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312Van Veldhuizen,P. J.; Hussey,M.; Lara,P. N.,Jr; Mack,P. C.; Gandour-Edwards,R.; Clark,J. I.; Lange,M. K.; Crawford,D. E.American Journal of Clinical Oncology 2009 ;32(5):453-459

Clinicopathological review: esthesioneuroblastomaBragg,T. M.; Scianna,J.; Kassam,A.; Emami,B.; Brown,H. G.; Hacein-Bey,L.; Clark,J. I.; Muzaffar,K.; Boulis,N.; Prabhu,V. C.Neurosurgery 2009 ;64(4):764-770

A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancerLee,R. T.; Beekman,K. E.; Hussain,M.; Davis,N. B.; Clark,J. I.; Thomas,S. P.; Nichols,K. F.; Stadler,W. M.CLINICAL GENITOURINARY CANCER 2008 ;6(1):21-24

Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation.Levey,S. A.; Bajwa,R. S.; Picken,M. M.; Clark,J. I.; Barton,K.; Leehey,D. J.NDT Plus 2008 ;3( ):154-156

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaSosman,J. A.; Carrillo,C.; Urba,W. J.; Flaherty,L.; Atkins,M. B.; Clark,J. I.; Dutcher,J.; Margolin,K. A.; Mier,J.; Gollob,J.; Kirkwood,J. M.; Panka,D. J.; Crosby,N. A.; O'Boyle,K.; LaFleur,B.; Ernstoff,M. S.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 ;26(14):2292-2298

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyAtkins,M. B.; Sosman,J. A.; Agarwala,S.; Logan,T.; Clark,J. I.; Ernstoff,M. S.; Lawson,D.; Dutcher,J. P.; Weiss,G.; Curti,B.; Margolin,K. A.Cancer 2008 ;113(8):2139-2145

Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.Hutchins,L. F.; Moon,J.; Clark,J. I.; Thompson,J. A.; Lange,M. K.; Flaherty,L. E.; Sondak,V. K.Cancer 2007 ;110(10):2269-2275

Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults.Meyer,P. N.; Clark,J. I.; Flanigan,R. C.; Picken,M. M.American Journal of Clinical Pathology 2007 ;128(1):70-79

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.Margolin,K.; Atkins,M. B.; Dutcher,J. P.; Ernstoff,M. S.; Smith,J. W.,2nd; Clark,J. I.; Baar,J.; Sosman,J.; Weber,J.; Lathia,C.; Brunetti,J.; Cihon,F.; Schwartz,B.Clinical Cancer Research 2007 ;13(11):3312-3319

Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.Clark,J. I.; Mehrabi,J.; Sosman,J. A.; Logan,T. F.; Margolin,K. A.; Dutcher,J. P.; Urba,W. J.; Ernstoff,M. S.; McDermott,D. F.; Lau,A. M.; Atkins,M. B.Journal of Immunotherapy 2007 ;30(8):839-846

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.Worden,F. P.; Moon,J.; Samlowski,W.; Clark,J. I.; Dakhil,S. R.; Williamson,S.; Urba,S. G.; Ensley,J.; Hussain,M. H.Cancer 2006 ;107(2):319-327

Vaccine therapy of malignant melanoma.Farray,D.; Clark,J. I.Clinical and applied immunology reviews 2006 ;6(3):217

Review.[comment]Farray,D.; Clark,J. I.Clinical Advances in Hematology & Oncology 2005 ;3(5):427-428

Neoadjuvant therapy: an emerging concept in oncologyTanvetyanon,T.; Clark,J. I.; Campbell,S. C.; Lo,S. S.Southern medical journal 2005 ;98(3):338-344

Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodes.Paner,G. P.; Turk,T. M.; Clark,J. I.; Lindgren,V.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2005 ;129(10):1317-1321

Metastatic Melanoma to the Central Nervous System: Case Report and Review of the LiteratureSchneck,M. J.; Patel,A.; Rodriguez-Quinonez,A.; Brown,H. G.; Clark,J. I.; Prabhu,V.; Dafer,R. M.; Biller,J.Seminars in Cerebrovascular Diseases and Stroke 2005 ;5(3):217-220

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaMcDermott,D. F.; Regan,M. M.; Clark,J. I.; Flaherty,L. E.; Weiss,G. R.; Logan,T. F.; Kirkwood,J. M.; Gordon,M. S.; Sosman,J. A.; Ernstoff,M. S.; Tretter,C. P.; Urba,W. J.; Smith,J. W.; Margolin,K. A.; Mier,J. W.; Gollob,J. A.; Dutcher,J. P.; Atkins,M. B.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 ;23(1):133-141

Metastatic juxtaglomerular cell tumor in a 52-year-old man.Duan,X.; Bruneval,P.; Hammadeh,R.; Fresco,R.; Eble,J. N.; Clark,J. I.; Vigneswaran,W. T.; Flanigan,R. C.; Picken,M. M.American Journal of Surgical Pathology 2004 ;28(8):1098-1102

Case report and brief review: IL-2-induced myocarditisEisner,R. M.; Husain,A.; Clark,J. I.Cancer investigation 2004 ;22(3):401-404

Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxelEdelman,M. J.; Clark,J. I.; Chansky,K.; Albain,K.; Bhoopalam,N.; Weiss,G. R.; Giguere,J. K.; Kelly,K.; Crowley,J.; Gandara,D. R.Clinical cancer research : an official journal of the American Association for Cancer Research 2004 ;10(15):5022-5026

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3Lathers,D. M.; Clark,J. I.; Achille,N. J.; Young,M. R.Cancer immunology, immunotherapy : CII 2004 ;53(5):422-430

Renal tumor with overlapping distal nephron morphology and karyotype.Lindgren,V.; Paner,G. P.; Flanigan,R. C.; Clark,J. I.; Campbell,S. C.; Picken,M. M.Archives of Pathology & Laboratory Medicine 2004 ;128(11):1274-1278

Metastatic renal cell carcinomaFlanigan,R. C.; Campbell,S. C.; Clark,J. I.; Picken,M. M.Current Treatment Options in Oncology 2003 ;4(5):385-390

Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynx.Petruzzelli,G. J.; Knight,F. K.; Vandevender,D.; Clark,J. I.; Emami,B.Otolaryngology - Head & Neck Surgery 2003 ;129(6):713-719

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.Clark,J. I.; Atkins,M. B.; Urba,W. J.; Creech,S.; Figlin,R. A.; Dutcher,J. P.; Flaherty,L.; Sosman,J. A.; Logan,T. F.; White,R.; Weiss,G. R.; Redman,B. G.; Tretter,C. P.; McDermott,D.; Smith,J. W.; Gordon,M. S.; Margolin,K. A.Journal of Clinical Oncology 2003 ;21(16):3133-3140

Nephrectomy in metastatic renal cell carcinomaCampbell,S. C.; Flanigan,R. C.; Clark,J. I.Current Treatment Options in Oncology 2003 ;4(5):363-372

Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosisNaeem,M.; Dahiya,M.; Clark,J. I.; Creech,S. D.; Alkan,S.Human pathology 2002 ;33(12):1182-1187

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019Albain,K. S.; Crowley,J. J.; Turrisi,A. T.,3rd; Gandara,D. R.; Farrar,W. B.; Clark,J. I.; Beasley,K. R.; Livingston,R. B.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 ;20(16):3454-3460

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient populationClark,J. I.; Kuzel,T. M.; Lestingi,T. M.; Fisher,S. G.; Sorokin,P.; Martone,B.; Viola,M.; Sosman,J. A.Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 2002 ;13(4):606-613

Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case reportRuzich,J. C.; Ciesla,M. C.; Clark,J. I.Head & neck 2002 ;24(4):406-410

Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia RegistryLipton,J. M.; Federman,N.; Khabbaze,Y.; Schwartz,C. L.; Hilliard,L. M.; Clark,J. I.; Vlachos,A.; Diamond-Black Anemia RegistryJournal of pediatric hematology/oncology 2001 ;23(1):39-44

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trialsFlaherty,L. E.; Atkins,M.; Sosman,J.; Weiss,G.; Clark,J. I.; Margolin,K.; Dutcher,J.; Gordon,M. S.; Lotze,M.; Mier,J.; Sorokin,P.; Fisher,R. I.; Appel,C.; Du,W.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 ;19(13):3194-3202

Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancerClark,J. I.; Kancharla,K.; Qamar,R.; Fisher,S.; Hantel,A.; Panganiban,J.; Millbrandt,L.; Albain,K. S.Lung cancer (Amsterdam, Netherlands) 2001 ;34(2):271-277

Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinomaClark,J. I.; Albain,K. S.Cancer treatment and research 2001 ;105( ):149-170

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.Clark,J. I.; Hofmeister,C.; Choudhury,A.; Matz,G.; Collins,S.; Bastian,R.; Melian,E.; Emami,B.; Petruzzelli,G.Cancer 2001 ;92(9):2334-2340

Patterns of spread in recurrent head and neck squamous cell carcinomaVaidya,A. M.; Petruzzelli,G. J.; Clark,J.; Emami,B.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2001 ;125(4):393-396

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancerAlmand,B.; Clark,J. I.; Nikitina,E.; van Beynen,J.; English,N. R.; Knight,S. C.; Carbone,D. P.; Gabrilovich,D. I.Journal of immunology (Baltimore, Md.: 1950) 2001 ;166(1):678-689

Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literaturePicken,M. M.; Curry,J. L.; Lindgren,V.; Clark,J. I.; Eble,J. N.The American Journal of Surgical Pathology 2001 ;25(11):1451-1457

Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patientsNikitina,E. Y.; Clark,J. I.; Van Beynen,J.; Chada,S.; Virmani,A. K.; Carbone,D. P.; Gabrilovich,D. I.Clinical cancer research : an official journal of the American Association for Cancer Research 2001 ;7(1):127-135

Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patientsLathers,D. M.; Clark,J. I.; Achille,N. J.; Young,M. R.Human immunology 2001 ;62(11):1282-1293

Clinical significance of defective dendritic cell differentiation in cancerAlmand,B.; Resser,J. R.; Lindman,B.; Nadaf,S.; Clark,J. I.; Kwon,E. D.; Carbone,D. P.; Gabrilovich,D. I.Clinical cancer research : an official journal of the American Association for Cancer Research 2000 ;6(5):1755-1766

New therapeutic strategies for the treatment and prevention of head and neck cancerLingen,M. W.; Emami,B.; Clark,J. I.Expert opinion on investigational drugs 2000 ;9(12):2855-2872

Education
Medical School
  • Loyola University Chicago Stritch School of Medicine
Residency
  • Loyola University Medical Center, Internal Medicine: General
Fellowship
  • Fox Chase Cancer Center/Temple University Hospital, Hematology & Medical Oncology
Interests
  • Reading
  • Triathlon